car-t cell

CAR-T 2.0

The field of cancer immunotherapies was buoyed last year by the FDA’s approval of the first autologous CAR-T drugs on the market, Novartis’ Kymriah and Gilead’s Yescarta. But, many drug makers are already looking in a new direction — off-the-shelf, or allogeneic, CAR-T therapies. In autologous therapies, like Kymriah and Yescarta, scientists isolate T cells from…